Evidence map›Paper›PMID 35347412›Full record

Trial reportWorld journal of urology2022

Variation across operating sites in urinary and sexual outcomes after radical prostatectomy in localized and locally advanced prostate cancer.

Nora Tabea Sibert, Holger Pfaff, Clara Breidenbach, Simone Wesselmann, Rebecca Roth, Günther Feick, Günter Carl, Sebastian Dieng, Amr A Gaber, Andreas Blana and 16 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in World journal of urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Nora Tabea SibertGerman Cancer Society, Kuno-Fischer-Straße 8, 14057, Berlin, Germany. sibert@krebsgesellschaft.de.ORCID http://orcid.org/0000-0001-6314-8158
Holger PfaffFaculty of Human Sciences, Faculty of Medicine and University Hospital Cologne, Institute of Medical Sociology, Health Services Research and Rehabilitation Science, University of Cologne, Eupener Str. 129, 50933, Cologne, Germany.
Clara BreidenbachGerman Cancer Society, Kuno-Fischer-Straße 8, 14057, Berlin, Germany.
Simone WesselmannGerman Cancer Society, Kuno-Fischer-Straße 8, 14057, Berlin, Germany.
Rebecca RothFaculty of Medicine and University Hospital Cologne, Institute of Medical Statistics and Computational Biology, University of Cologne, Robert-Koch-Str. 10, 50931, Cologne, Germany.
Günther FeickFederal Association of German Prostate Cancer Patient Support Groups, Bonn, Germany.
Günter CarlFederal Association of German Prostate Cancer Patient Support Groups, Bonn, Germany.
Sebastian DiengOnkoZert GmbH, Neu-Ulm, Germany.
Amr A GaberUrologische Klinik, Carl-Thiem-Klinikum Cottbus, Thiemstr. 111, 03048, Cottbus, Germany.
Andreas BlanaKlinik für Urologie und Kinderurologie, Klinikum Fürth, Jakob-Henle-Strasse 1, 90766, Fürth, Germany.
Christopher DarrKlinik für Urologie, Universitätsklinikum Essen, Hufelandstraße 55, 45147, Essen, Germany.
Florian DistlerKlinik für Urologie, Universitätsklinik der Paracelsus Medizinischen Privatuniversität, Standort Klinikum Nürnberg, Prof.-Ernst-Nathan-Straße 1 (Haus 22), 90419, Nuremberg, Germany.
Frank KunathDepartment of Urology and Pediatric Urology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), University Hospital Erlangen, Krankenhausstrasse 12, 91054, Erlangen, Germany.
Jens BedkeKlinik für Urologie, Universität Tübingen, Hoppe-Seyler-Str. 3, 72076, Tübingen, Germany.
Jörg ErdmannProstatakarzinomzentrum Tauber-Franken, Uhlandstr. 7, 97980, Bad Mergentheim, Germany.
Jörg MinnerHegau-Bodensee-Klinikum GmbH, Virchowstraße 10, 78224, Singen, Germany.
Jörg SimonKlinik für Urologie und Kinderurologie, Ortenau Klinikum, Ebertplatz 12, 77654, Offenburg, Germany.
Maciej KwiatkowskiKantonsspital Aarau AG, Onkologiezentrum Mittelland, Tellstrasse 25, 5001, Aarau, Switzerland.
Martin BurchardtKlinik und Poliklinik für Urologie, Universitätsmedizin Greifswald, Ferdinand-Sauerbruch-Straße, 17475, Greifswald, Germany.
Nino HarzKlinikum Dortmund, Münsterstraße 240, 44145, Dortmund, Germany.
Stefan ConradDIAKOVERE Friederikenstift, Humboldtstraße 5, 30169, Hannover, Germany.
Thomas HöfnerKlinik und Poliklinik für Urologie und Kinderurologie, UNIVERSITÄTSMEDIZIN der Johannes Gutenberg-Universität Mainz, Langenbeckstraße 1, 55131, Mainz, Germany.
Thomas KnollKliniken Sindelfingen, Arthur-Gruber-Str. 70, 71065, Sindelfingen, Germany.
Burkhard BeyerMartini-Klinik Prostate Cancer Center Hamburg, Martinistraße 52, 20246, Hamburg, Germany.
Peter HammererStädtisches Klinikum Braunschweig, Freisestraße 9/10, 38118, Braunschweig, Germany.
Christoph KowalskiGerman Cancer Society, Kuno-Fischer-Straße 8, 14057, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe extent of variation in urinary and sexual functional outcomes after radical prostatectomy (RPE) between prostate cancer (PC) operating sites remains unknown. Therefore, this analysis aims to compare casemix-adjusted functional outcomes (EPIC-26 scores incontinence, irritative/obstructive function and sexual function) between operating sites 12 months after RPE. MATERIALS AND

methodsAnalysis of a cohort of 7065 men treated with RPE at 88 operating sites (prostate cancer centers, "PCCs") between 2016 and 2019. Patients completed EPIC-26 and sociodemographic information surveys at baseline and 12 months after RPE. Survey data were linked to clinical data. EPIC-26 domain scores at 12 months after RPE were adjusted for relevant confounders (including baseline domain score, clinical and sociodemographic information) using regression analysis. Differences between sites were described using minimal important differences (MIDs) and interquartile ranges (IQR). The effects of casemix adjustment on the score results were described using Cohen's d and MIDs.

resultsAdjusted domain scores at 12 months varied between sites, with IQRs of 66-78 (incontinence), 89-92 (irritative/obstructive function), and 20-29 (sexual function). Changes in domain scores after casemix adjustment for sites ≥ 1 MID were noted for the incontinence domain (six sites). Cohen's d ranged between - 0.07 (incontinence) and - 0.2 (sexual function), indicating a small to medium effect of casemix adjustment.

conclusionsVariation between sites was greatest in the incontinence and sexual function domains for RPE patients. Future research will need to identify the factors contributing to this variation. TRIAL REGISTRY: The study is registered at the German Clinical Trial Registry ( https://www.drks.de/drks_web/ ) with the following ID: DRKS00010774.

Indexed as

Prostatic NeoplasmsUrinary IncontinenceUrinary TractHumansMaleProstateProstatectomyQuality of LifeCenter comparisonPatient-reported outcomesProstate cancerQuality assuranceRadical prostatectomy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.